Experienced in Pityriasis Rubra Pilaris

Dr. Aida Lugo

Dermatology
Office
410 Market St Ste 400, 
Chapel Hill, NC 
Experienced in Pityriasis Rubra Pilaris
Office
410 Market St Ste 400, 
Chapel Hill, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Aida Lugo is a Dermatologist in Chapel Hill, North Carolina. Dr. Lugo is rated as an Experienced provider by MediFind in the treatment of Pityriasis Rubra Pilaris. Her top areas of expertise are Contact Dermatitis, Psoriasis, Actinic Keratosis, and Epidermolysis Bullosa.

Her clinical research consists of co-authoring 27 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Puerto Rico School Of Medicine
Specialties
Dermatology
Licenses
Dermatology in PR
Hospital Affiliations
Unc Hospitals
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
TeamCare
  • OTHER COMMERCIAL
Trillium
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Office
410 Market St Ste 400, Chapel Hill, NC 27516
Other Locations
Office
Chapel Hill, NC 27599

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Vehicle-Controlled, Sample Size Adaptive Design Study to Evaluate the Safety and Efficacy of Topically Applied EB01 Cream in Healthy Adult Volunteers and Adult Subjects with Moderate to Severe Chronic Allergic Contact Dermatitis
A Randomized, Double-Blind, Vehicle-Controlled, Sample Size Adaptive Design Study to Evaluate the Safety and Efficacy of Topically Applied EB01 Cream in Healthy Adult Volunteers and Adult Subjects with Moderate to Severe Chronic Allergic Contact Dermatitis
Enrollment Status: Completed
Publish Date: November 14, 2024
Intervention Type: Drug
Study Drug: EB01 Cream
Study Phase: Phase 2
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum
Enrollment Status: Completed
Publish Date: January 11, 2022
Intervention Type: Combination product
Study Phase: Phase 3
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: September 27, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
Enrollment Status: Completed
Publish Date: March 30, 2021
Intervention Type: Drug
Study Phase: Phase 3
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Drug
Study Phase: Phase 4
A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa
A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa
Enrollment Status: Completed
Publish Date: April 09, 2020
Intervention Type: Drug
Study Phase: Phase 3
An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
Enrollment Status: Terminated
Publish Date: November 05, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Multicenter Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Adult Subjects With Pruritus Associated With Atopic Dermatitis
A Phase 2 Multicenter Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Adult Subjects With Pruritus Associated With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: December 13, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

27 Total Publications

Potential Allergens in Feminine Hygiene Products.
Potential Allergens in Feminine Hygiene Products.
Journal: Dermatitis : contact, atopic, occupational, drug
Published: September 30, 2025
Similar Doctors
Advanced in Pityriasis Rubra Pilaris
Dr. Nicholas Ross
Dermatology
Advanced in Pityriasis Rubra Pilaris
Dr. Nicholas Ross
Dermatology

Chapel Hill Dermatology

891 Willow Dr Ste 1, 
Chapel Hill, NC 
 (5.9 miles away)
919-942-3106
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dr. Ross was born in New York City, NY and graduated magna cum laude from Syracuse University. He was awarded his medical degree from Sidney Kimmel Medical College of Thomas Jefferson University in Philadelphia, Pennsylvania. While in Philadelphia, he completed his internship in medicine at Pennsylvania Hospital of the University of Pennsylvania Health System and dermatology residency at the Department of Dermatology & Cutaneous Biology of Thomas Jefferson University Hospital. After graduating, he was recruited as faculty at Thomas Jefferson University Hospital where he was promoted to Assistant Professor of Dermatology. In this role, he devoted a significant portion of his time to oversee resident physicians’ clinical training in addition to caring for his own patients.A Fellow of the American Academy of Dermatology, lifetime member of Alpha Omega Alpha Honors Society and member of the Gold Humanism Honors Society, Dr. Ross is active in the community. He has published dozens of peer-reviewed articles/chapters in medical journals and textbooks and has lectured as an invited speaker at local, national and international conferences regarding his research. Dr. Ross is rated as an Advanced provider by MediFind in the treatment of Pityriasis Rubra Pilaris. His top areas of expertise are Pityriasis Rubra Pilaris, Hidradenitis Suppurativa, Keloids, and Lichen Simplex Chronicus.

Advanced in Pityriasis Rubra Pilaris
Dr. Michel Gilliet
Dermatology
Advanced in Pityriasis Rubra Pilaris
Dr. Michel Gilliet
Dermatology

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (19.4 miles away)
713-792-6161
Languages Spoken:
English

Michel Gilliet is a Dermatologist in Cary, North Carolina. Dr. Gilliet is rated as an Advanced provider by MediFind in the treatment of Pityriasis Rubra Pilaris. His top areas of expertise are Rosacea, Psoriasis, Basal Cell Skin Cancer, and Perniosis.

John Murray
Advanced in Pityriasis Rubra Pilaris
Dr. John Murray
Dermatology
Advanced in Pityriasis Rubra Pilaris
Dr. John Murray
Dermatology

Duke Eye Center Of South Durham

234 Crooked Creek Pkwy, 
Durham, NC 
 (7.8 miles away)
919-385-7546
Languages Spoken:
English
See accepted insurances
Offers Telehealth

John Murray is a Dermatologist in Durham, North Carolina. Dr. Murray is rated as an Advanced provider by MediFind in the treatment of Pityriasis Rubra Pilaris. His top areas of expertise are Actinic Keratosis, Psoriasis, Seborrheic Keratosis, and Pityriasis Rubra Pilaris.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lugo's expertise for a condition
ConditionClose
      View All 22 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile